The effect of rivaroxaban for hemodynamics in left atrium and thrombotic / thrombolytic biomarkers

The effect of rivaroxaban for hemodynamics in left atrium and thrombotic / thrombolytic biomarkers - The effect of rivaroxaban for hemodynamics in left atrium and thrombotic / thrombolytic biomarkers

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000020806

Enrollment

Registered

2016-02-01

Start date

2016-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-valvular atrial fibrillation

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients with non-valvular persistent atrial fibrillation who have never been administered anticoagulants and whose transesophageal echo cardiography show spontaneous echo contrast in left atrium

Exclusion criteria

Exclusion criteria: paroxysmal atrial fibrillation obvious thrombus in LA or LAA cardiac tumor including myxoma contraindication of rivaroxaban creatinine clearance under 30ml/min unstable blood pressure control unstable control of blood sugar heart failure functional class NYHA 3 or 4 other unsuitable situation for this study

Design outcomes

Primary

Measure	Time frame
The disapperance of spontaneous echo contrast in LA after six-week administration of rivaroxaban when we observe LA by transesophageal echo cardiography	—

Countries

Japan

Contacts

Public ContactYasushi Imai

Jichi Medical University Division of Cardiovascular Medicine

imaiy@jichi.ac.jp0285-44-2111

Outcome results